Navigation Links
Pharsight Files Application for Nasdaq Capital Market Listing
Date:9/18/2007

MOUNTAIN VIEW, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has filed an application to list its common stock on the Nasdaq Capital Market. The Company will work with Nasdaq to complete the application process.

"This application is an important milestone for Pharsight," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Three years ago we embarked upon a strategy that we believed would lead to profitable revenue growth and enhanced value for our stockholders. Since that time, we have delivered consistent, positive net income and revenue growth. We believe the successful listing of Pharsight's common stock on the Nasdaq Capital Market will encourage an increase in our valuation, one that is more in-line with companies with similar dynamics and one that more adequately reflects our long-term opportunities for growth."

As part of the Nasdaq application and approval process, the Company must meet certain eligibility criteria. The Company believes it currently meets every eligibility criterion with the exception of a minimum bid price of $4. The Company's stockholders recently approved a reverse stock split, which, once completed, the Company believes will allow it to meet this final requirement.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight app
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Novartis files application with FDA for Zometa
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
4. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
5. Personality profiles of gamblers and substance abusers are similar
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Venus Remedies Files 5th International Patent Application
8. Shoaib Akhtar files appeal against ban
9. AIIMS Official Files Complaint Against Venugopal
10. Glaxo Files Cancer Drug For Approval With FDA
11. Nigeria Files New Lawsuit Against Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...als of public health interventions can cost hundre...hers// in this week’s BMJ argue that, if the scien...ne. Randomised controlled trials are usually requ...emented. But in 2003, the BMJ published an article...
...ersity (LLU) shows that adding just a handful of p...xidation of blood lipids// , thus helping reduce t... this positive effect was in part due to the pecan...'Plant foods, including pecans, are rich sources o...
...dial tibial stress syndrome, better known as shin ... conducted// at the University of Messina in Messi...stress syndrome is one of many overuse lower leg i...and accounts for between 13.2% and 17.3% of all ru...
...t has become more common in aged people. Exercise ...h joint // replacement as a treatment for the cond...thritis Care & Research examined whether asking pa...r knee replacement surgery would help in restoring...
Other Medicine News:Health News:Antioxidant-Rich Pecans Protect Against Unhealthy Oxidation in the Body 2Health News:Does Exercise Before Hip Replacement Help? 2
(Date:10/14/2008)... 14 /PRNewswire-USNewswire/ -- The Michael J. Fox,...l of $2 million to five,research teams to speed de...ressed cognitive and mood-related symptoms of Park...oms, which range from problems with,executive func...ute plans),to dementia; depression, apathy and anx...
(Date:10/13/2008)... Stent with Polyzene(R)-F Surface Treatment Maximi...ogenicity, Need for Long-Term,Dual Antiplatelet Th...al investigators at today,s,"Innovative Devices an...nual Transcatheter Cardiovascular Therapeutics (TC...scular Research Foundation, presented,12-month fol...
(Date:10/13/2008)...s., Oct. 13 /- Facet Solutions, Inc. ...p on 20 patients from its US,IDE Pilot Study. The ...y,Index (ODI) scores, and an 80% reduction in Visu...eoff Pardo, President & CEO for Facet Solutions,a...s, which thus far not,only demonstrate significant...
(Date:10/10/2008)... MENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall...that it plans to present,long-term follow-up data ...,week at the Cardiovascular Research Foundation,s ...r Therapeutics (TCT) meeting in Washington, DC.,Th...esigned to investigate,the safety and efficacy of ...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease 412-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2GSA Selects Cascades Technologies Inc 28CTi 29 to Support USA gov 2431 1GSA Selects Cascades Technologies Inc 28CTi 29 to Support USA gov 2431 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 1FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 4FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 5Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 1Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 2Kiwa Bio Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2427 3Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 1Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 2Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 3Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 1132 4
...Mullerian Inhibiting Substance (MIS), also known a...glycoprotein dimer composed of two 72 kDa monomers...to the transforming growth factor-? (TGF-?) superf... and activin glycoproteins (2). All members of thi...
The STA Compact CT is a completely automated, benchtop hemostasis analyzer capable of performing clotting assays in random access mode. The system's unique method of sample management offers high thr
...Alpha Fetoprotein (AFP) is a 68 kDa protein, which...tal liver and yolk sac [1]. Human fetal serum AFP...n rates reach 19-26 g/min during mid-gestation (14...es of total fetal AFP continue to increase after m...
Compensating for movement is critical to weighing patients in wheelchairs. Thats why this scale has the exclusive technology to do just that. Extremely durable, with state-of-the-art technology, thes
Medicine Products: